Clinical research in neonates and infants: Challenges and perspectives

Pharmacological Research

Volumn 108, Issue , 2016, Pages 80-87

  Coppini, Raffaele ^a   Simons, Sinno H P ^b   Mugelli, Alessandro ^a   Allegaert, Karel ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Aminoglycoside; Beta blockers; Paracetamol; Pediatrics; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; GENTAMICIN; IBUPROFEN; INDOMETACIN; NETILMICIN; PARACETAMOL; PROPRANOLOL; RANOLAZINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT;

ANTIARRHYTHMIC ACTIVITY; AREA UNDER THE CURVE; CATHETER ABLATION; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; KIDNEY DISEASE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; UNITED STATES; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; DRUG DEVELOPMENT; INFANT; NEWBORN; PEDIATRICS; PROCEDURES;

ANTI-BACTERIAL AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; INFANT; INFANT, NEWBORN; PEDIATRICS; PHARMACEUTICAL RESEARCH; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 84964912891     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.04.025     Document Type: Review

References (86)

1. E.M. Hsieh, C.P. Hornik, R.H. Clark, and et al. Medication use in the neonatal intensive care unit Am. J. Perinatol. 31 2014 811 822 10.1055/s-0033-1361933
2. S. Riou, F. Plaisant, D.M. Boulch, B. Kassai, O. Claris, and K.A. Nguyen Unlicensed and off-label drug use: a prospective study in French NICU Acta Paediatr. 104 2015 e228 e231 10.1111/apa.12924
3. M.M. Laughon, D. Avant, N. Tripathi, and et al. Drug labeling and exposure in neonates JAMA Pediatr. 168 2014 130 136 10.1001/jamapediatrics.2013.4208
4. J.L. Stiers, and R.M. Ward Newborns, one of the last therapeutic orphans to be adopted JAMA Pediatr. 168 2014 106 108 10.1001/jamapediatrics.2013.4604
5. K. Allegaert, and J. van den Anker Neonatal drug therapy: the first frontier of therapeutics for children Clin. Pharmacol. Ther. 98 2015 288 297 10.1002/cpt.166
6. J. Wang, D. Avant, D. Green, and et al. A survey of neonatal pharmacokinetic and pharmacodynamic studies in pediatric drug development Clin. Pharmacol. Ther. 98 2015 328 335 10.1002/cpt.149
7. J.M. Davis, and M.A. Turner Global collaboration to develop new and existing drugs for neonates JAMA Pediatr. 169 2015 887 888 10.1001/jamapediatrics.2015.1640
8. E. Manolis, and G. Pons Proposals for model-based paediatric medicinal development within the current European Union regulatory framework Br. J. Clin. Pharmacol. 68 2009 493 501 10.1111/j.1365-2125.2009.03484.x
9. R. Admiraal, C. van Kesteren, J.J. Boelens, R.G.M. Bredius, D. Tibboel, and C.A.J. Knibbe Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling Arch. Dis. Child. 99 2014 267 272 10.1136/archdischild-2013-303721
10. J. Samardzic, K. Allegaert, M. Wilbaux, M. Pfister, and J.N. van den Anker Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period Expert Opin. Drug Metab. Toxicol. 12 2016 367 375 10.1517/17425255.2016.1147559
11. W. Zhao, V. Biran, and E. Jacqz-Aigrain Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates Clin. Pharmacokinet. 52 2013 1127 1134 10.1007/s40262-013-0101-6
12. R.F.W. De Cock, C. Piana, E.H.J. Krekels, M. Danhof, K. Allegaert, and C.A.J. Knibbe The role of population PK-PD modelling in paediatric clinical research Eur. J. Clin. Pharmacol. 67 2011 S5 S16 10.1007/s00228-009-0782-9
13. R.F.W. De Cock, K. Allegaert, M.F. Schreuder, and et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance Clin. Pharmacokinet. 51 2012 105 117
14. A. Smits, R.F.W. De Cock, K. Allegaert, S. Vanhaesebrouck, M. Danhof, and C.A.J. Knibbe Prospective evaluation of a model-Based dosing regimen for amikacin in preterm and term neonates in clinical practice Antimicrob. Agents Chemother. 59 2015 6344 6351 10.1128/aac.01157-15
15. M. Wilbaux, A. Fuchs, J. Samardzic, and et al. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates J. Clin. Pharmacol. 2016 10.1002/jcph.705
16. T. Metsvaht, G. Nellis, H. Varendi, and et al. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination BMC Pediatr. 2015 15 10.1186/s12887-015-0359-y (ARTN 41)
17. P. Pokorna, E.D. Wildschut, V. Vobruba, J.N. van den Anker, and D. Tibboel The impact of hypothermia on the pharmacokinetics of drugs used in neonates and young infants Curr. Pharm. Des. 21 2015 5705 5724 10.2174/1381612821666150901110929
18. Y.A. Bijleveld, T.R. de Haan, J.H. van der Lee, and et al. Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia Br. J. Clin. Pharmacol. 2016 10.1111/bcp.12883
19. R.F.W. De Cock, K. Allegaert, C.M.T. Sherwin, and et al. A neonatal amikacin covariate model can Be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates Pharm. Res. Dordr. 31 2014 754 767 10.1007/s11095-013-1197-y
20. E.J.H. Janssen, P.A.J. Valitalo, K. Allegaert, and et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling Antimicrob. Agents Chemother. 60 2016 1013 1021 10.1128/aac.01968-15
21. P.A.J. Valitalo, J.N. van den Anker, K. Allegaert, and et al. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates J. Antimicrob. Chemoth. 70 2015 2074 2077 10.1093/jac/dkv052
22. A. Ohlsson, R. Walia, S. Shah, Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants, The Cochrane database of systematic reviews, 2008, CD003481, 10.1002/14651858, CD003481, pub3.
23. A. Ohlsson, R. Walia, S.S. Shah, Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants, The Cochrane database of systematic reviews, 2015, 2, CD003481, 10.1002/14651858, CD003481, pub6.
24. R. Neumann, S.M. Schulzke, and C. Buhrer Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis Neonatology 102 2012 9 15 10.1159/000335332
25. M.Y. Oncel, and O. Erdeve Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus World J. Clin. Pediatr. 5 2016 75 81 10.5409/wjcp.v5.i1.75
26. A. Ohlsson, P.S. Shah, Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants, The Cochrane database of systematic reviews, 2015, 3, CD010061, 10.1002/14651858, CD010061, pub2.
27. M.Y. Oncel, and O. Erdeve Safety of therapeutics used in management of patent ductus arteriosus in preterm infants Curr. Drug Saf. 10 2015 106 112
28. M.Y. Oncel, S. Yurttutan, H. Degirmencioglu, and et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants Neonatology 103 2013 166 169 10.1159/000345337
29. D. Dang, D. Wang, C. Zhang, W. Zhou, Q. Zhou, and H. Wu Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial PLoS One 8 2013 e77888 10.1371/journal.pone.0077888
30. M.Y. Oncel, S. Yurttutan, O. Erdeve, and et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial J. Pediatr. 164 2014 510 10.1016/j.jpeds.2013.11.008
31. K. Allegaert, B. Anderson, S. Simons, and B. van Overmeire Paracetamol to induce ductus arteriosus closure: is it valid? Arch. Dis. Child. 98 2013 462 466 10.1136/archdischild-2013-303688
32. B.J. Anderson Paracetamol (Acetaminophen): mechanisms of action Paediatr. Anaesth. 18 2008 915 921 10.1111/j.1460-9592.2008.02764.x
33. G.G. Graham, M.J. Davies, R.O. Day, A. Mohamudally, and K.F. Scott The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings Inflammopharmacology 21 2013 201 232 10.1007/s10787-013-0172-x
34. B. Hinz, O. Cheremina, and K. Brune Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man FASEB J. 22 2008 383 390 10.1096/fj.07-8506com
35. P. Erba, P. Harbi, T. Thacher, A. Pries, G. Ambrosio, and W. Raffoul Early detection of microcirculatory perfusion changes with a high resolution, real time laser Doppler imaging camera-frostbite case study BMJ Case Reports 2011 2011 10.1136/bcr.06.2011.4404
36. G.M. Pacifici, and K. Allegaert Clinical pharmacology of paracetamol in neonates: a review Curr. Ther. Res. Clin. Exp. 77 2015 24 30 10.1016/j.curtheres.2014.12.001
37. H. Viberg, P. Eriksson, T. Gordh, and A. Fredriksson Paracetamol (Acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice Toxicol. Sci. 138 2014 139 147 10.1093/toxsci/kft329
38. Z. Liew, B. Ritz, J. Virk, and J. Olsen Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: a Danish national birth cohort study Autism Res.: Off. J. Int. Soc. 2015 10.1002/aur.1591
39. Z. Liew, B. Ritz, C. Rebordosa, P.C. Lee, and J. Olsen Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders JAMA Pediatr. 168 2014 313 320 10.1001/jamapediatrics.2013.4914
40. J.P. Langhendries, K. Allegaert, J.N. Van den Anker, F. Veyckemans, and F. Smets Possible effects of repeated exposure to ibuprofen and acetaminophen on the intestinal immune response in young infants Med. Hypotheses 87 2016 90 96 10.1016/j.mehy.2015.11.012
41. A. Varvarigou, C.L. Bardin, K. Beharry, S. Chemtob, A. Papageorgiou, and J.V. Aranda Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants JAMA J. Am. Med. Assoc. 275 1996 539 544 10.1001/jama.275.7.539
42. D. Hirt, B. Van Overmeire, J.M. Treluyer, and et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study Br. J. Clin. Pharmacol. 65 2008 629 636 10.1111/j.1365-2125.2008.03118.x
43. S.P. Seslar, M.M. Garrison, C. Larison, and J.C. Salerno A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants Pediatr. Cardiol. 34 2013 408 414 10.1007/s00246-012-0474-6
44. S.N. Weindling, J.P. Saul, and E.P. Walsh Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants Am. Heart J. 131 1996 66 72
45. M.C. Tavera, P.P. Bassareo, P. Neroni, and et al. Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma J. Matern. Fetal Neonatal Med. 23 Suppl. 3 2010 30 33 10.3109/14767058.2010.517937
46. K.K. Wong, J.E. Potts, S.P. Etheridge, and S. Sanatani Medications used to manage supraventricular tachycardia in the infant - a North American survey Pediatr. Cardiol. 27 2006 199 203 10.1007/s00246-005-1126-x
47. S. Sanatani, J.E. Potts, J.H. Reed, and et al. The study of antiarrhythmic medications in infancy (SAMIS) a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants Circ. Arrhythmia Elec. 5 2012 984 991 10.1161/Circep.112.972620
48. C.P. Hornik, P.Y. Chu, J.S. Li, R.H. Clark, P.B. Smith, and K.D. Hill Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants Pediatr. Crit. Care Med. 15 2014 839 845 10.1097/Pcc.0000000000000229
49. B.S. Moffett, P.J. Lupo, C.M. delaUz, and et al. Efficacy of digoxin in comparison with propranolol for treatment of infant supraventricular tachycardia: analysis of a large, national database Cardiol. Young 25 2015 1080 1085 10.1017/S10479511140 01619
50. A.L. Barton, B.S. Moffett, S.O. Valdes, C. Miyake, and J.J. Kim Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias J. Pediatr. 166 2015 115 118 10.1016/j.jpeds.2014.08.067
51. M. Gheorghiade, K.F. Adams, and W.S. Colucci Digoxin in the management of cardiovascular disorders Circulation 109 2004 2959 2964 10.1161/01.Cir.0000132482.95686.87
52. D.J. Goodman, R.M. Rossen, D.S. Cannom, A.K. Rider, and D.C. Harrison Effect of digoxin on atioventricular conduction: studies in patients with and without cardiac autonomic innervation Circulation 51 1975 251 256
53. K.M. Ali Collateral effects of antiarrhythmics in pediatric age Curr. Pharm. Des. 14 2008 782 787
54. Y. Gong, Y. Chen, Q. Li, and Z. Li Population pharmacokinetic analysis of digoxin in Chinese neonates and infants J. Pharmacol. Sci. 125 2014 142 149
55. M. Yukawa, E. Yukawa, F. Suematsu, and et al. Population pharmacokinetic investigation of digoxin in Japanese infants and young children J. Clin. Pharmacol. 51 2011 857 863 10.1177/0091270010374475
56. A. Smits, A. Kulo, J.N. de Hoon, and K. Allegaert Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations Curr. Pharm. Des. 18 2012 3119 3146
57. D.E. Sweeney, V. Vallon, T. Rieg, W. Wu, T.F. Gallegos, and S.K. Nigam Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney Mol. Pharmacol. 80 2011 147 154 10.1124/mol.110.070680
58. I. Ostman-Smith Beta-blockers in pediatric hypertrophic cardiomyopathies Rev. Recent Clin. Trials 9 2014 82 85
59. B.J. Maron, W.C. Roberts, and S.E. Epstein Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients Circulation 65 1982 1388 1394
60. D.G. Shand, C.G. Sell, and J.A. Oates Hypertrophic obstructive cardiomyopathy in an infant-propranolol therapy for three years N. Engl. J. Med. 285 1971 843 844 10.1056/NEJ M197110072851507
61. I. Ostman-Smith, G. Wettrell, and T. Riesenfeld A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment J. Am. Coll. Cardiol. 34 1999 1813 1822
62. J.E. Brush Jr., G. Eisenhofer, M. Garty, and et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy Circulation 79 1989 836 844
63. I. Ostman-Smith Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat Br. J. Pharmacol. 116 1995 2703 2709
64. J.R. Skinner, A. Manzoor, A.M. Hayes, H.S. Joffe, and R.P. Martin A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants Heart 77 1997 229 233
65. J.A. Decker, J.W. Rossano, E.O. Smith, and et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children J. Am. Coll. Cardiol. 54 2009 250 264 10.1016/j.jacc.2009.03.051
66. C. Bourmayan, A. Razavi, C. Fournier, and et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study Am. Heart J. 109 1985 1311 1316
67. F. Gentile, R. Coppini, C. Ferrantini, and et al. Life-Long treatment with late sodium current blocker reduces myocardial dysfunction and remodeling in a mouse model of hypertrophic cardiomyopathy Biophys. J. 108 2015 291a 10.1016/j.bpj.2014.11.1588
68. R. Coppini, C. Ferrantini, L. Yao, and et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy Circulation 127 2013 575 584 10.1161/CIRCULATIONAHA.112.134932
69. R. Spoladore, M.S. Maron, R. D'Amato, P.G. Camici, and I. Olivotto Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence Eur. Heart J. 33 2012 1724 1733 10.1093/eurheartj/ehs150
70. I. Ostman-Smith Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death Fundam. Clin. Pharmacol. 24 2010 637 652 10.1111/j.1472-8206.2010.00869.x
71. S. Albers, B. Meibohm, T.S. Mir, and S. Laer Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure Br. J. Clin. Pharmacol. 65 2008 511 522 10.1111/j.1365-2125.2007.03046.x
72. J.E. Brush, G. Eisenhofer, M. Garty, and et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy Circulation 79 1989 836 844
73. S.F. Zhou Polymorphism of human cytochrome P450 2D6 and its clinical significance part I Clin. Pharmacokinet. 48 2009 689 723
74. L. Filippi, G. Cavallaro, P. Fiorini, and et al. Propranolol concentrations after oral administration in term and preterm neonates J. Matern. Fetal Neo. Med. 26 2013 833 840 10.3109/14767058.2012.755169
75. M.A. Turner, and U. Shah Why are excipients important to neonates Curr. Pharm. Des. 21 2015 5680 5687
76. M.A. Turner Neonatal drug development Early Hum. Dev. 87 2011 763 768 10.1016/j.earlhumdev.2011.08.014
77. M.W. Linakis, J.K. Roberts, A.C. Lala, and et al. Challenges associated with route of administration in neonatal drug delivery Clin. Pharmacokinet. 55 2016 185 196 10.1007/s40262-015-0313-z
78. K. Allegaert, B.J. Anderson, V. Cossey, and N.H.G. Holford Limited predictability of amikacin clearance in extreme premature neonates at birth Br. J. Clin. Pharmacol. 61 2006 39 48 10.1111/j.1365-2125.2005.02530.x
79. A. Campino, E. Santesteban, P. Pascual, and et al. Strategies implementation to reduce medicine preparation error rate in neonatal intensive care units Eur. J. Pediatr. 2015 10.1007/s00431-015-2679-1
80. G. Nellis, T. Metsvaht, H. Varendi, and et al. Potentially harmful excipients in neonatal medicines: a pan-European observational study Arch. Dis. Child. 100 2015 694 699 10.1136/archdischild-2014-307793
81. V. Klingmann, A. Seitz, T. Meissner, J. Breitkreutz, A. Moeltner, and H.M. Bosse Acceptability of uncoated mini-tablets in Neonates - a randomized controlled trial J. Pediatr. 167 2015 893 896e2 10.1016/j.jpeds.2015.07.010
82. K. Allegaert, S. Vanhaesebrouck, A. Kulo, and et al. Prospective assessment of short-term propylene glycol tolerance in neonates Arch. Dis. Child. 95 2010 1054 1058 10.1136/adc.2010.190330
83. R.F. De Cock, C.A. Knibbe, A. Kulo, and et al. Developmental pharmacokinetics of propylene glycol in preterm and term neonates Br. J. Clin. Pharmacol. 75 2013 162 171 10.1111/j.1365-2125.2012.04312.x
84. H. Mulla, S. Yakkundi, J. McElnay, and et al. An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates Pharm. Res. 32 2015 1084 1093 10.1007/s11095-014-1520-2
85. J.M. Davis, and M.A. Turner Global collaboration to develop new and existing drugs for neonates JAMA Pediatr. 169 2015 887 888 10.1001/jamapediatrics.2015.1640
86. R.M. Ward, and C.M. Sherwin Ethics of drug studies in the newborn Paediatr. Drugs 17 2015 37 42 10.1007/s40272-014-0099-8